CONNECT WITH US
HealthTech

HealthTech

RFK Jr. eases access to unproven peptides despite opposition from FDA scientists

Medical Xpress logo

Published on

Add as a preferred source on Google
RFK Jr. eases access to unproven peptides despite opposition from FDA scientists

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

The Trump administration on Wednesday acted to ease access to unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr. Food and Drug Administration scientific staffers had little input on the decision and opposed the changes, according to six people familiar with its development.

The draft policy posted online by Kennedy's Department of Health and Human Services covers a handful of injectable peptides promoted within the wellness industry for uses such as building muscle, healing injuries and boosting energy. The government will take comments for two weeks before finalizing the measure.

The document, primarily written by officials at HHS, faced overwhelming pushback among FDA drug staffers who warned it could undermine the agency's long-standing mission of keeping unsafe health products off the U.S. market, according to the people familiar with its development.

The people spoke to The Associated Press on the condition of anonymity to discuss confidential government deliberations.

The policy directs the FDA not to take action against specialty pharmacies that sell a half-dozen wellness peptides, including BPC-157, TB-500 and KPV. Under normal FDA rules, those chemicals would be considered illegal drugs because they have not gone through the agency's rigorous review process for safety and effectiveness.

According to the document posted online, Kennedy determined the change "advances patient choice and freedom" while protecting people in the United States from peptides sold online that are often made from ingredients of unknown origin and quality.


Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.